Acne Vulgaris: Global Prevalence Update
Acne Vulgaris is a common skin disorder characterized by the appearance of pimples, blackheads, cysts, and nodules. Although it predominantly affects adolescents, it can occur at any age. The condition arises due to excessive sebum production and clogged hair follicles, which result in inflammation. While acne is generally not life-threatening, it can significantly affect a person’s quality of life, leading to psychological distress, scarring, and social stigma. Treatment mainly aims to reduce inflammation, bacterial growth, and sebum production.
Explore key stats, market drivers, and emerging drugs—all in one visual!: https://www.delveinsight.com/infographics/acne-vulgaris-av-market?utm_source=infographics&utm_medium=promotion&utm_campaign=hpr
Acne Vulgaris Epidemiological Segmentation
The epidemiological segmentation of Acne Vulgaris in the
7MM from 2020 to 2034 includes:
Total prevalent cases of Acne Vulgaris
Total diagnosed prevalent cases of Acne Vulgaris
Gender-specific diagnosed prevalent cases of Acne Vulgaris
Severity-specific diagnosed prevalent cases of Acne Vulgaris
Treatable cases of Acne Vulgaris
Acne Vulgaris Epidemiology
In 2023, about 140.2 million cases of Acne Vulgaris were reported across the 7MM, with the United States accounting for approximately 69.5 million cases. These figures are expected to increase during the forecast period.
In the 7MM, diagnosed Acne Vulgaris cases were more common among females, representing 63% of the total diagnosed cases.
Regarding severity in the 7MM:
Moderate cases were the most common, comprising 45% of diagnosed cases.
Severe cases were the least common, accounting for only 10% of total cases.
One graphic, all the essentials—click to explore!: https://www.delveinsight.com/report-store/acne-vulgaris-av-market?utm_source=infographics&utm_medium=promotion&utm_campaign=hpr
Acne Vulgaris Market
The total market size for Acne Vulgaris in the 7MM was estimated at around USD 4.26 billion in 2023.
Acne Vulgaris Market Drivers
The emergence of new therapies such as SB204, DMT310, and BTX 1503 is anticipated to improve treatment options by offering more targeted, effective, and safer solutions for Acne Vulgaris.
Increasing awareness of the condition, especially its psychological effects, along with enhanced diagnostic capabilities, is expected to boost growth in the Acne Vulgaris treatment market.
Acne Vulgaris Market Barriers
The varied clinical presentations of Acne Vulgaris and inconsistent responses to treatment—particularly in moderate and severe cases—make therapy development and approval challenging, resulting in unpredictable treatment outcomes.
High treatment costs, especially for newer and advanced therapies, combined with limited healthcare access in certain regions, may restrict market expansion.
Acne Vulgaris Emerging Therapies
SB204
DMT310
BTX 1503
B244
BPX-01
And others
Acne Vulgaris Key Players
Pelthos Therapeutics
Dermata Therapeutics
Botanix Pharmaceuticals
AOBiome LLC
BioPharmX
Timber Pharmaceuticals
And others
Grab your free copy of the infographic—essential for any analyst!: https://www.delveinsight.com/infographics/acne-vulgaris-av-market?utm_source=infographics&utm_medium=promotion&utm_campaign=hpr
Acne Vulgaris is a common skin disorder characterized by the appearance of pimples, blackheads, cysts, and nodules. Although it predominantly affects adolescents, it can occur at any age. The condition arises due to excessive sebum production and clogged hair follicles, which result in inflammation. While acne is generally not life-threatening, it can significantly affect a person’s quality of life, leading to psychological distress, scarring, and social stigma. Treatment mainly aims to reduce inflammation, bacterial growth, and sebum production.
Explore key stats, market drivers, and emerging drugs—all in one visual!: https://www.delveinsight.com/infographics/acne-vulgaris-av-market?utm_source=infographics&utm_medium=promotion&utm_campaign=hpr
Acne Vulgaris Epidemiological Segmentation
The epidemiological segmentation of Acne Vulgaris in the
7MM from 2020 to 2034 includes:
Total prevalent cases of Acne Vulgaris
Total diagnosed prevalent cases of Acne Vulgaris
Gender-specific diagnosed prevalent cases of Acne Vulgaris
Severity-specific diagnosed prevalent cases of Acne Vulgaris
Treatable cases of Acne Vulgaris
Acne Vulgaris Epidemiology
In 2023, about 140.2 million cases of Acne Vulgaris were reported across the 7MM, with the United States accounting for approximately 69.5 million cases. These figures are expected to increase during the forecast period.
In the 7MM, diagnosed Acne Vulgaris cases were more common among females, representing 63% of the total diagnosed cases.
Regarding severity in the 7MM:
Moderate cases were the most common, comprising 45% of diagnosed cases.
Severe cases were the least common, accounting for only 10% of total cases.
One graphic, all the essentials—click to explore!: https://www.delveinsight.com/report-store/acne-vulgaris-av-market?utm_source=infographics&utm_medium=promotion&utm_campaign=hpr
Acne Vulgaris Market
The total market size for Acne Vulgaris in the 7MM was estimated at around USD 4.26 billion in 2023.
Acne Vulgaris Market Drivers
The emergence of new therapies such as SB204, DMT310, and BTX 1503 is anticipated to improve treatment options by offering more targeted, effective, and safer solutions for Acne Vulgaris.
Increasing awareness of the condition, especially its psychological effects, along with enhanced diagnostic capabilities, is expected to boost growth in the Acne Vulgaris treatment market.
Acne Vulgaris Market Barriers
The varied clinical presentations of Acne Vulgaris and inconsistent responses to treatment—particularly in moderate and severe cases—make therapy development and approval challenging, resulting in unpredictable treatment outcomes.
High treatment costs, especially for newer and advanced therapies, combined with limited healthcare access in certain regions, may restrict market expansion.
Acne Vulgaris Emerging Therapies
SB204
DMT310
BTX 1503
B244
BPX-01
And others
Acne Vulgaris Key Players
Pelthos Therapeutics
Dermata Therapeutics
Botanix Pharmaceuticals
AOBiome LLC
BioPharmX
Timber Pharmaceuticals
And others
Grab your free copy of the infographic—essential for any analyst!: https://www.delveinsight.com/infographics/acne-vulgaris-av-market?utm_source=infographics&utm_medium=promotion&utm_campaign=hpr
Acne Vulgaris: Global Prevalence Update
Acne Vulgaris is a common skin disorder characterized by the appearance of pimples, blackheads, cysts, and nodules. Although it predominantly affects adolescents, it can occur at any age. The condition arises due to excessive sebum production and clogged hair follicles, which result in inflammation. While acne is generally not life-threatening, it can significantly affect a person’s quality of life, leading to psychological distress, scarring, and social stigma. Treatment mainly aims to reduce inflammation, bacterial growth, and sebum production.
Explore key stats, market drivers, and emerging drugs—all in one visual!: https://www.delveinsight.com/infographics/acne-vulgaris-av-market?utm_source=infographics&utm_medium=promotion&utm_campaign=hpr
Acne Vulgaris Epidemiological Segmentation
The epidemiological segmentation of Acne Vulgaris in the
7MM from 2020 to 2034 includes:
Total prevalent cases of Acne Vulgaris
Total diagnosed prevalent cases of Acne Vulgaris
Gender-specific diagnosed prevalent cases of Acne Vulgaris
Severity-specific diagnosed prevalent cases of Acne Vulgaris
Treatable cases of Acne Vulgaris
Acne Vulgaris Epidemiology
In 2023, about 140.2 million cases of Acne Vulgaris were reported across the 7MM, with the United States accounting for approximately 69.5 million cases. These figures are expected to increase during the forecast period.
In the 7MM, diagnosed Acne Vulgaris cases were more common among females, representing 63% of the total diagnosed cases.
Regarding severity in the 7MM:
Moderate cases were the most common, comprising 45% of diagnosed cases.
Severe cases were the least common, accounting for only 10% of total cases.
One graphic, all the essentials—click to explore!: https://www.delveinsight.com/report-store/acne-vulgaris-av-market?utm_source=infographics&utm_medium=promotion&utm_campaign=hpr
Acne Vulgaris Market
The total market size for Acne Vulgaris in the 7MM was estimated at around USD 4.26 billion in 2023.
Acne Vulgaris Market Drivers
The emergence of new therapies such as SB204, DMT310, and BTX 1503 is anticipated to improve treatment options by offering more targeted, effective, and safer solutions for Acne Vulgaris.
Increasing awareness of the condition, especially its psychological effects, along with enhanced diagnostic capabilities, is expected to boost growth in the Acne Vulgaris treatment market.
Acne Vulgaris Market Barriers
The varied clinical presentations of Acne Vulgaris and inconsistent responses to treatment—particularly in moderate and severe cases—make therapy development and approval challenging, resulting in unpredictable treatment outcomes.
High treatment costs, especially for newer and advanced therapies, combined with limited healthcare access in certain regions, may restrict market expansion.
Acne Vulgaris Emerging Therapies
SB204
DMT310
BTX 1503
B244
BPX-01
And others
Acne Vulgaris Key Players
Pelthos Therapeutics
Dermata Therapeutics
Botanix Pharmaceuticals
AOBiome LLC
BioPharmX
Timber Pharmaceuticals
And others
Grab your free copy of the infographic—essential for any analyst!: https://www.delveinsight.com/infographics/acne-vulgaris-av-market?utm_source=infographics&utm_medium=promotion&utm_campaign=hpr
0 Comments
0 Shares
26 Views